Sinopharm posts unaudited Q1 2026 figures, highlighting RMB 400.8bn asset base

Sinopharm Group Co ( (HK:1099) ) just unveiled an update.

Sinopharm Group Co. Ltd. has released unaudited consolidated and standalone financial information for the three months ended 31 March 2026, prepared under PRC GAAP, as required by regulators in the mainland and Hong Kong. The disclosure covers balance sheets, income statements and cash flow statements for the group and the parent company, highlighting a substantial asset base of about RMB 400.8 billion and indicating continued large-scale operations in pharmaceutical distribution.

The quarterly figures show current assets rising to roughly RMB 356.1 billion, driven by higher accounts receivables and inventories, while non-current assets remained broadly stable around RMB 44.7 billion. This update enhances transparency for bond and equity investors by providing an early snapshot of Sinopharm’s 2026 financial position, and underscores the group’s compliance with cross-border reporting standards as it manages liquidity, credit exposure and growth in China’s healthcare market.

The most recent analyst rating on (HK:1099) stock is a Buy with a HK$22.50 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.

More about Sinopharm Group Co

Sinopharm Group Co. Ltd. is a major pharmaceutical distributor and healthcare services provider in China, operating through a network of subsidiaries with listings in Hong Kong and on mainland exchanges. The group focuses on wholesale and retail distribution of medicines and medical supplies, as well as related healthcare logistics and services across the domestic market.

YTD Price Performance: -1.13%

Average Trading Volume: 5,686,485

Technical Sentiment Signal: Hold

Current Market Cap: HK$59.98B

Find detailed analytics on 1099 stock on TipRanks’ Stock Analysis page.